Other
U.S. Food and Drug Administration (FDA)
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed trials have results
Key Signals
1 recruiting
Enrollment Performance
Analytics
Phase 2
1(33.3%)
Phase 1
1(33.3%)
Phase 4
1(33.3%)
3Total
Phase 2(1)
Phase 1(1)
Phase 4(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT06953726Phase 4Not Yet Recruiting
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
Role: collaborator
NCT05338632Phase 1Recruiting
Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists
Role: collaborator
NCT03981523Phase 2Completed
New Therapies and Biomarkers for Chagas Infection
Role: collaborator
All 3 trials loaded